Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Gerald Brennan vice president, administrative and financial operations, and chief financial officer. It also named Timothy Mayleben to its board.

Adenosine Therapeutics LLC, of Charlottesville, Va., promoted William Stilley to chief operating officer, Robert Thompson to vice president of chemistry and Joel Linden to chairman.

AdipoGenix Inc., of Boston, appointed Nils Bergenhem chief scientific officer.

Adolor Corp., of Exton, Pa., appointed Kevin Taylor vice president, business development, and Randall Mack vice president, project management.

Aegera Therapeutics Inc., of Montreal, appointed Jacques Jolivet vice president, clinical development.

AlphaVax, of Research Triangle Park, N.C., said its president, Peter Young, was elected to the boards of the Biotechnology Industry Organization and of the North Carolina Biosciences Organization.

Amazon Biotech Inc., of New York, appointed Simcha Edell chief financial officer, and retained the services of Meir Spear as its internal accountant.

Ascentia Biomedical Corp., of Bellevue, Wash., appointed Emil Chi chairman and Richard Darveau and Keith Knutson members of its scientific advisory board.

AtheroGenics Inc., of Atlanta, appointed Joseph Gaynor vice president and general counsel.

BioMarin Pharmaceutical Inc., of Novato, Calif., appointed Stephen Aselage senior vice president, global commercial operations.

BIOQuebec, of Montreal, appointed Genevieve Foster to its board.

Biosite Inc., of San Diego, appointed Norman Paradis vice president, medical affairs and promoted Elaine Walton to vice president, quality assurance and program management.

Callisto Pharmaceuticals Inc., of New York, appointed Riccardo Dalla-Favera to its board.

CancerVax Corp., of Carlsbad, Calif., appointed Jeffrey Silverman vice president, manufacturing operations, and promoted Martin Mattingly to executive vice president and chief operating officer. It also named Hazel Aker senior vice president, regulatory operations and legal affairs, and Carol Gallagher vice president, sales, marketing and product planning.

Celsion Corp., of Columbia, Md., appointed Gregory Weaver to its board and a member of the audit committee.

Codexis Inc., of Redwood City, Calif., said its president and CEO, Alan Shaw, was appointed to chair the Biotechnology Industry Organization's industrial and environmental section.

EnVivo Pharmaceuticals Inc., of Watertown, Mass., appointed Kees Been CEO.

Genentech Inc., of South San Francisco, appointed David Broad vice president and general manager; John Pinion vice president, external quality; and Michael Varney vice president, small-molecule drug discovery.

Genstruct Inc., of Cambridge, Mass., appointed Alan Williamson to its scientific advisory board and Charlie Lieu director of business development and marketing.

Halozyme Therapeutics Inc., of San Diego, appointed Steve Thornton to its board.

ImClone Systems Inc., of New York, named David Sidransky vice chairman of its board.

Inhibitex Inc., of Atlanta, appointed Sam Michini vice president of sales and marketing.

Interleukin Genetics Inc., of Waltham, Mass., appointed Ramon Mohanlal chief medical officer.

Invitrogen Corp., of Carlsbad, Calif., appointed Peter Leddy senior vice president of human resources.

Isolagen Inc., of Exton, Pa., appointed Marie Lindner senior vice president of medical and business affairs.

IsoTis OrthoBiologics, of Lausanne, Switzerland, appointed James Hart to its board.

Kai Pharmaceuticals Inc., of South San Francisco, appointed Daria Mochly-Rosen, Robert Bell, Richard DiMarchi, Steven Dowdy, Eric Gordon, Randy Schekman, Susan Taylor and Robert Tjian to its scientific advisory board.

MacroGenics Inc., of Rockville, Md., appointed Nelson Campbell and Ronald Wilder to its senior management team, and promoted Ezio Bonvini to vice president of research, and Joseph Panigot to vice president of legal affairs.

Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Constance Bienfait vice president of investor relations, and said its CEO Thomas McLain was appointed to the Biotechnology Industry Organization's board.

NABsys, of Providence, R.I., appointed Barrett Bready CEO.

Nanosphere Inc., of Northbrook, Ill., appointed Gregory Shipp vice president of medical affairs.

Neogen Corp., of Lansing, Mich., said its vice president of scientific affairs, Joseph Madden, was appointed to the National Advisory Committee on Microbiological Criteria for Foods.

NeoGenomics Inc., of Fort Myers, Fla., appointed Thomas Conrad, George O'Leary and Peter Peterson to its board.

NeoRx Corp., of Seattle, appointed David Karlin senior vice president of clinical development and regulatory affairs.

Neurocrine Biosciences Inc., of San Diego, appointed Richard Ranieri senior vice president of human resources.